Comprehensive genomic characterization of squamous cell lung cancers
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite many additional doublings in culture, this point mutational frequency (2.16 per Mb) is on the lower end of frequencies observed across different cancer genomes22.”
From The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Genomic characterization of squamous cell lung cancers showed significant alterations in the Nrf2 pathway in 34% of all tumour specimens examined [175].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [175]
In the citing paper
“Combined PI3K and CDK4/6 inhibition may also be of substantial interest in squamous cell NSCLC and head and neck cancer, where amplification of both CCND1 and PIK3CA are common events (117, 118), as well as in pancreatic cancer, where genetically engineered mouse models have suggested the importance of the PI3K pathway downstream from activated KRAS (119).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [118]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“2); (2) confirmation of the altered allele in RNA sequencing; and (3) the mutation assessor score(40).”
BackgroundPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Cited by
Items 601–700 of 1,021
Suzuki, A., Makinoshima, H., Wakaguri, H., Esumi, H., Sugano, S., Kohno, T., Tsuchihara, K., & Suzuki, Y. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku885 · Cited by 126
Stueve, T. R., Li, W., Shi, J., Marconett, C. N., Zhang, T., Yang, C., Mullen, D. J., Yan, C., Wheeler, W., Hua, X., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx188 · Cited by 122
Porrello, A., Leslie, P. L., Harrison, E. B., Gorentla, B. K., Kattula, S., Ghosh, S. K., Azam, S. H., Holtzhausen, A., Chao, Y. L., Hayward, M. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04355-w · Cited by 115
Tam, K. W., Zhang, W., Soh, J., Stastny, V., Chen, M., Sun, H., Thu, K., Rios, J. J., Yang, C., Marconett, C. N., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a46c0c · Cited by 109
Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic
Levine, B. D., & Cagan, R. L. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.105 · Cited by 123
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
George, J., Saito, M., Tsuta, K., Iwakawa, R., Shiraishi, K., Scheel, A. H., Uchida, S., Watanabe, S.-I., Nishikawa, R., Noguchi, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1069 · Cited by 108
Pereira, C., Gimenez-Xavier, P., Pros, E., Pajares, M. J., Moro, M., Gomez, A., Navarro, A., Condom, E., Moran, S., Gomez-Lopez, G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1946 · Cited by 109
TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy
McLoughlin, M. R., Orlicky, D. J., Prigge, J. R., Krishna, P., Talago, E. A., Cavigli, I. R., Eriksson, S., Miller, C. G., Kundert, J. A., Sayin, V. I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903244116 · Cited by 108
Omics-based nanomedicine: The future of personalized oncology
Rosenblum, D., & Peer, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.029 · Cited by 117
Mohni, K. N., Thompson, P. S., Luzwick, J. W., Glick, G. G., Pendleton, C. S., Lehmann, B. D., Pietenpol, J. A., & Cortez, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125482 · Cited by 108
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O’Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 107
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry
Kluk, M., Ashworth, T. D., Wang, H., Knoechel, B., Mason, E. F., Morgan, E. A., Dorfman, D. M., Pinkus, G., Weigert, O., Hornick, J. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067306 · Cited by 111
Comprehensive genomic characterization of squamous cell lung cancers
McCullough, A. J. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.11.048 · Cited by 108
Wang, M., Zhang, G., Zhang, Y., Cui, X., Wang, S., Gao, S., Wang, Y., Liu, Y., Bae, J. H., Yang, W., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1033 · Cited by 120
Targeting tumor suppressor genes for cancer therapy
Liu, Y., Hu, X., Han, C., Wang, L., Zhang, X., He, X., & Lu, X. (2015) · BioEssays · doi:10.1002/bies.201500093 · Cited by 107
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Heist, R. S., Shim, H. S., Gingipally, S., Mino-Kenudson, M. A., Le, L. P., Gainor, J. F., Zheng, Z., Aryee, M. J., Xia, J., Jia, P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0510 · Cited by 121
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Halvorsen, A. R., Silwal‐Pandit, L., Meza‐Zepeda, L. A., Vodák, D., Vu, P., Sagerup, C., Hovig, E. J., Myklebost, O., Børresen‐Dale, A., Brustugun, O. T., et al. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00085 · Cited by 110
Herreros‐Pomares, A., de-Maya-Girones, J. D., Fariñas, S. C., Lucas-Domínguez, R., Martínez‐Romero, A., Pardo-Sánchez, J. M., Alonso, S., Blasco, A., Guijarro, R., Martorell, M., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1898-1 · Cited by 120
Signaling pathways in HPV‐associated cancers and therapeutic implications
Chen, J. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1823 · Cited by 118
Rosendahl Huber, A., Pleguezuelos-Manzano, C., Puschhof, J., Ubels, J., Boot, C., Saftien, A., Verheul, M., Trabut, L. T., Groenen, N., van Roosmalen, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.009 · Cited by 106
Hedgehog–GLI Signaling Inhibition Suppresses Tumor Growth in Squamous Lung Cancer
Huang, L., Walter, V., Hayes, D. N., & Onaitis, M. W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2195 · Cited by 116
Nie, J., Liu, L., Li, X., & Han, W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.010 · Cited by 105
Deoxynyboquinones as NQO1-Activated Cancer Therapeutics
Parkinson, E. I., & Hergenrother, P. J. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00365 · Cited by 108
Exosomal lipids for classifying early and late stage non-small cell lung cancer
Fan, T. W. ‐., Zhang, X., Wang, C., Yang, Y., Kang, W.-Y., Arnold, S. M., Higashi, R. M., Liu, J., & Lane, A. N. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.02.051 · Cited by 113
Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer
Malý, V., Malý, O., Kološtová, K., & Bobek, V. (2019) · In Vivo · doi:10.21873/invivo.11571 · Cited by 116
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
Γκουντάκος, Α., Sartori, G., Falcone, I., Piro, G., Ciuffreda, L., Carbone, C., Tortora, G., Scarpa, A., Bria, E., Milella, M., et al. (2019) · Cancers · doi:10.3390/cancers11081141 · Cited by 115
Sun, H., Cao, S., Mashl, R. J., Mo, C.-K., Zaccaria, S., Wendl, M. C., Davies, S. R., Bailey, M. H., Primeau, T. M., Hoog, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25177-3 · Cited by 113
Composition and Function of Mammalian SWI/SNF Chromatin Remodeling Complexes in Human Disease
Pulice, J. L., & Kadoch, C. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031021 · Cited by 106
Processed pseudogenes acquired somatically during cancer development
Cooke, S. L., Shlien, A., Marshall, J., Pipinikas, C. P., Martincorena, I., Tubio, J. M. C., Li, Y., Menzies, A., Mudie, L., Ramakrishna, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms4644 · Cited by 105
Intergenically Spliced Chimeric RNAs in Cancer
Jia, Y., Xie, Z., & Li, H. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.006 · Cited by 115
netDx: interpretable patient classification using integrated patient similarity networks
Pai, S., Hui, S., Isserlin, R., Shah, M. A., Kaka, H., & Bader, G. D. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188497 · Cited by 103
Jiang, T., Shi, J., Dong, Z., Hou, L., Zhao, C., Li, X., Mao, B., Zhu, W., Guo, X., Zhang, H., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0762-1 · Cited by 121
Bergom, C. R., West, C., Higginson, D. S., Abazeed, M. E., Arun, B., Bentzen, S. M., Bernstein, J. L., Evans, J. D., Gerber, N. K., Kerns, S. L., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.07.026 · Cited by 111
Wong, C. C., Baum, J., Silvestro, A., Beste, M. T., Bharani-Dharan, B., Xu, S., Wang, Y. A., Wang, X., Prescott, M. F., Krajkovich, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3176 · Cited by 105
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Conforti, F., Pala, L., Pagan, E., Bagnardi, V., Pas, T. M. D., Queirolo, P., Pennacchioli, E., Catania, C., Cocorocchio, E., Ferrucci, P. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0136 · Cited by 120
A pan-cancer organoid platform for precision medicine
Larsen, B. M., Kannan, M., Langer, L. F., Leibowitz, B. D., Bentaieb, A., Cancino, A., Dolgalev, I., Drummond, B. E., Dry, J. R., Ho, C.-S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109429 · Cited by 105
Liang, W.-W., Lu, R. J.-H., Jayasinghe, R. G., Foltz, S. M., Porta-Pardo, E., Geffen, Y., Wendl, M. C., Lazcano, R., Kolodziejczak, I., Song, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.013 · Cited by 105
Self-citationCharacterization of Somatic Mutations in Air Pollution-Related Lung Cancer
Yu, X., Yang, M., Zhou, B., Wang, G., Huang, Y., Wu, L., Cheng, X., Wen, Z., Huang, J.-Y., Zhang, Y., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.04.003 · Cited by 105
Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0971 · Cited by 104
Entropy-based consensus clustering for patient stratification
Liu, H., Zhao, R., Fang, H., Cheng, F., Fu, Y., & Liu, Y. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx167 · Cited by 110
The Impact of Genomic Changes on Treatment of Lung Cancer
Cardarella, S., & Johnson, B. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201305-0843pp · Cited by 104
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2020) · Purinergic Signalling · doi:10.1007/s11302-020-09711-4 · Cited by 112
A Survey of Machine Learning Approaches Applied to Gene Expression Analysis for Cancer Prediction
Khalsan, M., Machado, L. R., Al-Shamery, E. S., Ajit, S., Anthony, K., Mu, M., & Agyeman, M. O. (2022) · IEEE Access · doi:10.1109/access.2022.3146312 · Cited by 121
Sox2 Cooperates with Lkb1 Loss in a Mouse Model of Squamous Cell Lung Cancer
Mukhopadhyay, A., Berrett, K. C., Kc, U., Clair, P. M., Pop, S. M., Carr, S. R., Witt, B. L., & Oliver, T. G. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.036 · Cited by 103
Pangeni, R. P., Channathodiyil, P., Huen, D. S., Eagles, L., Johal, B. K., Pasha, D., Hadjistephanou, N., Nevell, O., Davies, C. L., Adewumi, A. I., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0089-x · Cited by 106
Cancer genome-sequencing study design
Mwenifumbo, J. C., & Marra, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3445 · Cited by 120
Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years
Čufer, T., Ovčariček, T., & O'Brien, M. E. R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.021 · Cited by 107
A Short History of Chromosome Rearrangements and Gene Fusions in Cancer
Mitelman, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_1 · Cited by 103
A machine learning approach for somatic mutation discovery
Wood, D. E., White, J. R., Georgiadis, A., Van Emburgh, B., Parpart-Li, S., Mitchell, J., Anagnostou, V., Niknafs, N., Karchin, R., Papp, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7939 · Cited by 103
Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA
Semenkovich, N. P., Szymanski, J. J., Earland, N. J., Chauhan, P. S., Pellini, B., & Chaudhuri, A. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006284 · Cited by 125
Liu, Q., Ghosh, P., Magpayo, N., Testa, M., Tang, S., Gheorghiu, L., Biggs, P. J., Paganetti, H., Efstathiou, J. A., Lu, H., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.12.046 · Cited by 110
Tian, W., Rojo de la Vega, M., Schmidlin, C. J., Ooi, A., & Zhang, D. D. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000428 · Cited by 98
Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy
Lattanzi, M. W., Lee, Y., Simpson, D., Moran, U., Darvishian, F., Kim, R. H., Hernando, E., Polsky, D., Hanniford, D., Shapiro, R. L., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy086 · Cited by 116
Toward A variable RBE for proton beam therapy
Willers, H., Allen, A. R., Grosshans, D. R., McMahon, S. J., von Neubeck, C., Wiese, C., & Vikram, B. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.05.019 · Cited by 111
A cloud-based workflow to quantify transcript-expression levels in public cancer compendia
Tatlow, P., & Piccolo, S. R. (2016) · Scientific Reports · doi:10.1038/srep39259 · Cited by 101
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 111
Anatomic position determines oncogenic specificity in melanoma
Weiss, J. M., Hunter, M. V., Cruz, N. M., Baggiolini, A., Tagore, M., Ma, Y., Misale, S., Marasco, M., Simon-Vermot, T., Campbell, N. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04584-6 · Cited by 101
Migliozzi, S., Oh, Y. T., Hasanain, M., Garofano, L., D’Angelo, F., Najac, R. D., Pïcca, A., Bielle, F., Stefano, A. L. D., Lerond, J., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00510-x · Cited by 108
WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies
Aldaz, C. M., Ferguson, B. W., & Abba, M. C. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.06.001 · Cited by 105
Holm, K., Staaf, J., Lauss, M., Aine, M., Lindgren, D., Bendahl, P., Vallon‐Christersson, J., Barkardottir, R. B., Höglund, M., Borg, Å., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0685-5 · Cited by 109
Primase-polymerases are a functionally diverse superfamily of replication and repair enzymes
Guilliam, T. A., Keen, B. A., Brissett, N. C., & Doherty, A. J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv625 · Cited by 106
Understanding genomic alterations in cancer genomes using an integrative network approach
Wang, E. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.050 · Cited by 102
Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function
Cabanski, C. R., White, N. M. A., Dang, H. X., Silva-Fisher, J., Rauck, C. E., Cicka, D., & Maher, C. A. (2015) · RNA Biology · doi:10.1080/15476286.2015.1038012 · Cited by 99
EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Yan, K.-S., Lin, C., Liao, T.-W., Peng, C.-M., Lee, S.-C., Liu, Y., Chan, W. P., & Chou, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061172 · Cited by 101
Identifying Epistasis in Cancer Genomes: A Delicate Affair
van de Haar, J., Canisius, S., Yu, M., Voest, E. E., Wessels, L. F. A., & Ideker, T. (2019) · Cell · doi:10.1016/j.cell.2019.05.005 · Cited by 99
Li, V. D., Li, K. H. L., & Li, J. T. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2817-z · Cited by 109
Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition
Ding, H., Chen, Z., Wu, K., Huang, S. M., Wu, W., LeBoeuf, S. E., Pillai, R., Rabinowitz, J. D., & Papagiannakopoulos, T. Y. (2021) · Science Advances · doi:10.1126/sciadv.abk1023 · Cited by 102
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Pan, Y., Han, H., Hu, H., Wang, H., Song, Y., Yuan, H., Tong, X., Patel, A. S., Misirlioğlu, S., Tang, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.015 · Cited by 112
The evolving genomic classification of lung cancer
Shames, D. S., & Wistuba, I. I. (2014) · The Journal of Pathology · doi:10.1002/path.4275 · Cited by 98
Orr, B., & Compton, D. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00164 · Cited by 123
Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas
Hammerman, P. S., Hayes, D. N., & Grandis, J. R. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1205 · Cited by 109
Early Events in the Molecular Pathogenesis of Lung Cancer
Kadara, H. N., Scheet, P. A., Wistuba, I. I., & Spira, A. E. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0400 · Cited by 112
Ulahannan, D., Kovac, M. B., Mulholland, P. J., Cazier, J., & Tomlinson, I. P. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.416 · Cited by 114
Redox Signaling by the RNA Polymerase III TFIIB-Related Factor Brf2
Gouge, J., Satia, K., Guthertz, N., Widya, M., Thompson, A. J., Cousin, P., Dergai, O., Hernandez, N., & Vannini, A. (2015) · Cell · doi:10.1016/j.cell.2015.11.005 · Cited by 102
Characterizing genomic alterations in cancer by complementary functional associations
Kim, J. W., Botvinnik, O. B., Abudayyeh, O., Birger, C., Rosenbluh, J., Shrestha, Y., Abazeed, M. E., Hammerman, P. S., DiCara, D., Konieczkowski, D. J., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3527 · Cited by 96
Genomic insights into head and neck cancer
Beck, T. N., & Golemis, E. A. (2016) · Cancers of the Head & Neck · doi:10.1186/s41199-016-0003-z · Cited by 104
Gene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer
Bhalla, S., Chaudhary, K., Kumar, R., Sehgal, M., Kaur, H., Sharma, S., & Raghava, G. P. S. (2017) · Scientific Reports · doi:10.1038/srep44997 · Cited by 108
Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer
Inamura, K. (2017) · Cells · doi:10.3390/cells6020012 · Cited by 111
Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities
Jung, B.-J., Yoo, H.-S., Shin, S., Park, Y., & Jeon, S. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.195 · Cited by 108
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 113
Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers
Okazaki, K., Anzawa, H., Liu, Z., Ota, N., Kitamura, H., Onodera, Y., Alam, M. M., Matsumaru, D., Suzuki, T., Katsuoka, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19593-0 · Cited by 94
Machine learning application in personalised lung cancer recurrence and survivability prediction
Yang, Y., Xu, L., Sun, L., Zhang, P., & Farid, S. S. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.03.035 · Cited by 115
Song, L., Smith, M. A., Doshi, P., Sasser, K., Fulp, W., Altiok, S., & Haura, E. B. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000193 · Cited by 97
Xu, J., Wang, J., Hu, Y., Qian, J., Xu, B., Chen, H., Zou, W., & Fang, J.-Y. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.75 · Cited by 96
A Histologic Basis for the Efficacy of SBRT to the lung
Woody, N. M., Stephans, K. L., Andrews, M., Zhuang, T., Gopal, P., Xia, P., Farver, C. F., Raymond, D. P., Peacock, C. D., Cicenia, J. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.002 · Cited by 100
Iijima, Y., Hirotsu, Y., Amemiya, K., Ooka, Y., Mochizuki, H., Oyama, T., Nakagomi, T., Uchida, Y., Kobayashi, Y., Tsutsui, T., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.004 · Cited by 99
Qin, A., Johnson, A., Ross, J. S., Miller, V. A., Ali, S. M., Schrock, A. B., & Gadgeel, S. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.014 · Cited by 96
Fang, S., Dai, Y., Mei, Y., Yang, M., Hu, L., Yang, H., Guan, X., & Li, J. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12947 · Cited by 96
Analysis of gene expression profiles of lung cancer subtypes with machine learning algorithms
Yuan, F., Lü, L., & Zou, Q. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165822 · Cited by 110
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Santarpía, M., Liguori, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., D’Aveni, A., Marabello, G., Altavilla, G., & Rosell, R. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s119644 · Cited by 124
PDGF Receptors in Tumor Biology: Prognostic and Predictive Potential
Paulsson, J., Ehnman, M., & Östman, A. (2014) · Future Oncology · doi:10.2217/fon.14.83 · Cited by 95
König, K., Peifer, M., Fassunke, J., Ihle, M. A., Künstlinger, H., Heydt, C., Stamm, K., Ueckeroth, F., Vollbrecht, C., Bos, M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000570 · Cited by 95
Luo, L., McGarvey, P. B., Madhavan, S., Kumar, R., Gusev, Y., & Upadhyay, G. (2016) · Oncotarget · doi:10.18632/oncotarget.7163 · Cited by 107
Smolle, E., & Pichler, M. (2019) · Cancers · doi:10.3390/cancers11020204 · Cited by 109
Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer
Honeycutt, J. D., Hammam, O. A., Fu, C., & Hsieh, M. H. (2014) · Trends in Parasitology · doi:10.1016/j.pt.2014.05.004 · Cited by 105
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 101
Surgery for NSCLC in the era of personalized medicine
Mitsudomi, T., Suda, K., & Yatabe, Y. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.22 · Cited by 102
Malchers, F., Dietlein, F., Schöttle, J., Lu, X., Nogova, L., Albus, K., Fernandez-Cuesta, L., Heuckmann, J. M., Gautschi, O., Diebold, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0323 · Cited by 94
BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Hall, R. D., & Kudchadkar, R. R. (2014) · Cancer Control · doi:10.1177/107327481402100307 · Cited by 93
Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia
Haider, S., McIntyre, A., van Stiphout, R. G. P. M., Winchester, L. M., Wigfield, S., Harris, A. L., & Buffa, F. M. (2016) · Genome Biology · doi:10.1186/s13059-016-0999-8 · Cited by 93
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2012-09-09
- Volume
- 489
- Issue
- 7417
- Pages
- 519-525
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3466113
- OpenAlex
- W2275877493
- Cited by
- 3,994
- References
- 45
- Citations by year
- 2026: 153 · 2025: 181 · 2024: 189 · 2023: 204 · 2022: 262 · 2021: 296 · 2020: 360 · 2019: 286 · 2018: 329 · 2017: 353 · 2016: 346 · 2015: 371 · 2014: 335 · 2013: 300 · 2012: 24
- FWCI
- 263.50
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-11-07)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- eSpace (Curtin University) (submittedVersion, cc-by-nc-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (5r01ca149569-05)
- BC Cancer Agency
- National Human Genome Research Institute (U54HG003067, HG003067, U54HG003079, HG003079, HG003273, U54HG003273, R01HG006272)
- National Cancer Institute (R01CA094143, U24CA126554, U24CA143882, R01-CA149569, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24CA143845, U24CA126544, R00CA149182, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, T32CA009172, P30CA016672, P30CA016086)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung squamous cell carcinoma, genetic alterations, epigenomic alterations, TP53 mutation, copy number alterations, genome rearrangement, Nrf2, Keap1, PI3K signaling, CDKN2A, RB1, therapeutic target, TCGA
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Squamous Cell, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Gene Deletion, Phosphatidylinositol 3-Kinases, Genes, p16, Gene Expression Profiling, Genomics, Molecular Targeted Therapy, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.